David Faleck

Dr. David Faleck is a Clinical Professor of Gastroenterology at Memorial Sloan Kettering Cancer Center (MSKCC), specializing in treating gastrointestinal (GI) complications of immunotherapy and managing inflammatory bowel disease (IBD). He leads research on immune-related enterocolitis and IBD-associated cancer risks. Dr. Faleck graduated from Albert Einstein College of Medicine, completed residencies at Columbia University Medical Center, and a fellowship at Mount Sinai Hospital.

Education:

• MD, Albert Einstein College of Medicine
• Residency: Internal Medicine, Columbia University Medical Center/New York-Presbyterian
• Fellowship: Gastroenterology, Mount Sinai Hospital

Research Interests:

Dr. Faleck focuses on immunotherapy-induced GI toxicities, IBD management in cancer patients, and colorectal cancer prevention in IBD. His work includes clinical trials investigating fecal microbiota transplantation for colitis and novel biomarkers for intestinal cancers in IBD.

Awards & Recognition:

• Castle Connolly America’s Top Doctor (2023–2025)
• Excellence in Outpatient Care Collaboration Award (2023)
• Chanel Endowment Award for Survivorship Research (2023)

Clinical Expertise:

Director of Inflammatory and Immune-Related Bowel Diseases at MSKCC. Specializes in colonoscopy, polypectomy, and chromoendoscopy. Works closely with oncologists to manage immunotherapy side effects and prevent IBD-related cancers.

Labs & Teams:

Leads multi-disciplinary teams addressing GI complications in oncology. Collaborates with researchers on microbiome studies and clinical trials for immune-related adverse events.